Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 121 publications

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.

Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.

Journal: Cancer biology & medicine
Published: September 30, 2025

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Journal: Seminars in hematology
Published: August 21, 2025

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: July 13, 2025

Glofitamab with GemOx for diffuse large B-cell lymphoma - Authors' reply.

Glofitamab with GemOx for diffuse large B-cell lymphoma - Authors' reply.

Journal: Lancet (London, England)
Published: July 09, 2025

Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.

Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.

Journal: Cancers
Published: July 08, 2025

Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.

Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical medicine
Published: July 03, 2025

Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada.

Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada.

Journal: Current oncology (Toronto, Ont.)
Published: July 02, 2025

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.

Journal: Cancers
Published: June 29, 2025

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

Journal: Cancers
Published: June 26, 2025

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 18, 2025

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.

Journal: Frontiers in oncology
Published: June 05, 2025

Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.

Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report.

Journal: Frontiers in immunology
Published: May 26, 2025
Showing 1-12 of 121

Last Updated: 10/31/2025